IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting
IMNN-001 immunotherapy plus standard-of-care chemotherapy resulted in 35% improvement in overall survival and 25% improvement in progression-free survival versus standard-of-care alone Treatment was ...
Zika Virus Therapeutics Market Research 2024-2030: Growing Use Of RNA-Based Therapeutics In Treatment Expands Opportunities
The growth in the Zika virus therapeutics market is driven by several factors, including the increasing global incidence of Zika outbreaks, the rising demand for preventive measures such as vaccines, ...
Sysco Reports First Quarter Fiscal Year 2025 Results
Sysco Corporation (NYSE: SYY) (“Sysco” or the “company”) today announced financial results for its 13-week first fiscal quarter ended September 28, 2024. Key financial results for the first quarter of ...
PulseSight Therapeutics Presents New Data on PST-611 Transferrin Vectorized Therapy for Geographic Atrophy at EVER Congress 2024
PulseSight plans to submit a phase I clinical trial authorization (CTA) by the end the year, to be closely followed by a phase II proof-of-concept to demonstrate the efficacy and the safety of its ...
TMCnet18d
Fractile licenses Andes Technology's RISC-V vector processor as it builds radical new chip to accelerate AI inference
San Jose, CA, Oct. 22, 2024 (GLOBE NEWSWIRE ... AI companies large and small since its debut in 2023. Andes RISC-V vector processors have enabled many AI SoCs to break free from architecture ...
Crowdfund Insider18h
SteelFox Exploits Foxit PDF Editor, AutoCAD for Banking Data Theft and Covert Crypto Mining – Report
The initial attack vector involves posts on forums and torrent trackers, where the SteelFox dropper is “advertised as a way ...
Finanznachrichten3d
Rapid7 Announces Third Quarter 2024 Financial Results
free cash flow of $39 million BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Rapid7, Inc. (Nasdaq: RPD), a leader in extended risk and threat detection, today announced its financial results for the third ...
Pharmabiz18h
Transgene & NEC to present new data confirming clinical proof of principle for neoantigen cancer vaccine, TG4050, in head & neck cancer at SITC 2024
After a median follow up of 24.1 months, all 16 patients who received TG4050 as adjuvant immunotherapy after completion of an adjuvant standard of care remain disease-free and have not ... to patients ...
The Columbian7d
University of Washington tries to weather storm of setbacks for misinformation researchers
It’s election season, and as falsehoods rain down like a monsoon, the “rapid research” team of academics at the University of Washington’s Center for an Informed Public has been scrambling to analyze ...
Spokane Public Radio7d
UW is trying to weather a storm of setbacks for misinformation researchers
Political pressure, loss of access to data from social media sites have made it harder to study how falsehoods spread for ...
East Idaho News9d
This university is trying to weather a storm of setbacks for misinformation researchers
It’s election season, and as falsehoods rain down like a monsoon, the “rapid research” team of academics at the University of ...
The University of Washington is trying to weather a storm of setbacks for misinformation researchers
Twitter, the site Starbird spent nearly 15 years studying, was purchased by billionaire Elon Musk — a fervent supporter of former President Trump — who rebranded it X and used it to personally spread ...